- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04665050
Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)
September 27, 2023 updated by: Merck Sharp & Dohme LLC
A Phase 1, Randomized, Double-blind, Active-Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Healthy Japanese Adults.
The purpose of this study is to compare the safety, tolerability, and immunogenicity of a polyvalent pneumococcal conjugate vaccine (V116) with that of PNEUMOVAX™23 in healthy Japanese adults.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
102
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Fukuoka, Japan, 812-0025
- Souseikai PS Clinic ( Site 0201)
-
Kumamoto, Japan, 861-4157
- Souseikai Nishikumamoto Hospital ( Site 0202)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- is a healthy Japanese male or female ≥20 years of age at time of randomization
- male participants must agree to be abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention
- female participants must not be pregnant or breastfeeding, and is either:
- not a woman of childbearing potential (WOCBP) or
- a WOCBP who agrees to remain abstinent or use contraception during the intervention period and for ≥30 days after the last dose of study intervention
Exclusion Criteria:
- has a history of invasive pneumococcal disease (IPD) within 3 years of Day 1
- has a known hypersensitivity to any vaccine components
- has impaired immunological function
- has a coagulation disorder
- had a recent febrile illness (axillary temperature ≥37.5°C or equivalent) within 72 hours before Day 1
- has a known malignancy that is progressing/requiring treatment
- has received, or is expected to receive, a pneumococcal vaccine outside the study protocol
- has received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for ≥14 consecutive days and has not completed the regimen for ≥30 days prior to Day 1
- is receiving immunosuppressive therapy
- has received any non-live vaccine from 14 days prior to Day 1 other than inactivated influenza vaccine
- has received any live vaccine from 30 days prior to Day 1
- has received a blood transfusion or blood products
- has participated in another clinical trial within 2 months of this study
- has clinically relevant drug or alcohol abuse
- has any condition that, in the opinion of the investigator, precludes participation in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: V116
Participants receive a single 1.0 mL intramuscular (IM) injection of V116 on Day 1.
|
Pneumococcal 21-valent conjugate vaccine with 2 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution
Other Names:
|
Active Comparator: PNEUMOVAX™23
Participants receive a single 0.5 mL IM injection of PNEUMOVAX™23 on Day 1.
|
Pneumococcal 23-valent polyvalent vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Solicited Injection-site Adverse Event (AE)
Time Frame: Up to 5 days postvaccination
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Solicited injection-site AEs included tenderness/pain, redness/erythema, and swelling.
The percentage of participants with one or more solicited injection-site AE was reported for each arm.
|
Up to 5 days postvaccination
|
Percentage of Participants With a Solicited Systemic AE
Time Frame: Up to 5 days postvaccination
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Solicited systemic AEs included headache, muscle pain/myalgia, joint pain/arthralgia, and tiredness/fatigue.
The percentage of participants with one or more solicited systemic AE was reported for each arm.
|
Up to 5 days postvaccination
|
Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)
Time Frame: Up to 62 days postvaccination
|
An SAE is an AE that results in death, is life threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment.
SAEs that were reported by the investigator to be at least possibly related to the study vaccination were reported.
|
Up to 62 days postvaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the Common Serotypes in V116 and PNEUMOVAX™23
Time Frame: Day 30 postvaccination
|
The serotype-specific OPA GMTs for serotypes common to V116 and PNEUMOVAX™23 were determined using the multiplex opsonophagocytic assay (MOPA).
Serotype-specific OPA GMTs and GMT ratios with 95% confidence intervals (CIs) were calculated using a constrained longitudinal data analysis (cLDA) model.
Per protocol, within-group measures of dispersion (MOD) were not calculated.
|
Day 30 postvaccination
|
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the Common Serotypes in V116 and PNEUMOVAX™23
Time Frame: Day 30 postvaccination
|
The GMCs for serotype-specific pneumococcal IgG antibodies were measured using pneumococcal electrochemiluminescence (PnECL).
Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model.
Per protocol, within-group MOD were not calculated.
|
Day 30 postvaccination
|
Serotype-specific OPA GMTs for the Unique Serotypes in V116
Time Frame: Day 30 postvaccination
|
The serotype-specific OPA GMTs for serotypes unique to V116 were determined using the MOPA.
Serotype-specific OPA GMTs and GMT ratios with 95% CIs were calculated using a cLDA model.
Per protocol, within-group MOD were not calculated.
|
Day 30 postvaccination
|
Serotype-specific IgG GMCs for the Unique Serotypes in V116
Time Frame: Day 30 postvaccination
|
The GMCs for serotype-specific pneumococcal IgG antibodies unique to V116 were measured using PnECL.
Serotype-specific pneumococcal IgG GMCs and GMC ratios with 95% CIs were calculated using a cLDA model.
Per protocol, within-group MOD were not calculated.
|
Day 30 postvaccination
|
Geometric Mean Fold Rise (GMFR) From Baseline in GMTs of Serotype-specific OPA
Time Frame: Baseline (Day 1) and Day 30 postvaccination
|
GMTs for the serotypes in V116 and PNEUMOVAX™23 were determined using the MOPA at baseline and 30 days post vaccination and derived from a cLDA model.
The GMFR (Day 30 GMT/Day 1 GMT) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
|
Baseline (Day 1) and Day 30 postvaccination
|
GMFR From Baseline in Serotype-specific IgG GMCs
Time Frame: Baseline (Day 1) and Day 30 postvaccination
|
GMCs for the serotypes in V116 and PNEUMOVAX™23 were measured by PnECL at baseline and 30 days post vaccination and derived from a cLDA model.
The GMFR (Day 30 GMC/Day 1 GMC) from baseline (Day 1) to Day 30 of each pneumococcal serotype was calculated.
|
Baseline (Day 1) and Day 30 postvaccination
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Director, Merck Sharp & Dohme LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 4, 2021
Primary Completion (Actual)
April 6, 2021
Study Completion (Actual)
April 6, 2021
Study Registration Dates
First Submitted
December 8, 2020
First Submitted That Met QC Criteria
December 8, 2020
First Posted (Actual)
December 11, 2020
Study Record Updates
Last Update Posted (Actual)
October 4, 2023
Last Update Submitted That Met QC Criteria
September 27, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- pPCV-002 (Other Identifier: Merck)
- jRCT2071200094 (Registry Identifier: jRCT)
- V116-002 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pneumococcal Infection
-
King Saud UniversityUnknown
-
London School of Hygiene and Tropical MedicineUniversity College, London; Bill and Melinda Gates Foundation; Wellcome Trust; KEMRI-Wellcome... and other collaboratorsActive, not recruitingPneumococcal Infection | Streptococcus Pneumoniae Infection | Invasive Pneumococcal Disease, Protection AgainstKenya
-
LG ChemCompletedPneumococcal InfectionKorea, Republic of
-
PfizerCompletedPneumococcal InfectionChina
-
National Institute of Allergy and Infectious Diseases...Completed
-
ImmunoBiology LimitedSimbec Research; ORION Clinical Services; Oxford Therapeutics Consulting LimitedCompletedPneumococcal InfectionUnited Kingdom
-
PfizerCompletedPneumococcal InfectionChina
-
Merck Sharp & Dohme LLCRecruitingPneumococcal InfectionFrance, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden
-
Merck Sharp & Dohme LLCCompletedPneumococcal InfectionUnited States, Australia, Belgium, Chile, Germany, Korea, Republic of, New Zealand, Puerto Rico, Sweden, Taiwan, Turkey
-
Merck Sharp & Dohme LLCCompletedPneumococcal Infection
Clinical Trials on V116
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompletedPneumococcal DiseaseUnited States, Austria, Canada, Denmark, Finland, Israel, Poland, Spain
-
Merck Sharp & Dohme LLCRecruitingPneumococcal InfectionFrance, United States, Japan, Canada, Turkey, Finland, Spain, Poland, Sweden
-
Merck Sharp & Dohme LLCActive, not recruitingPneumococcal DiseaseArgentina, Australia, Colombia, Germany, Israel, Korea, Republic of, New Zealand, Spain, Taiwan, Turkey, United Kingdom
-
Merck Sharp & Dohme LLCCompletedPneumococcal DiseaseJapan
-
Merck Sharp & Dohme LLCCompletedPneumonia, PneumococcalUnited States, Canada, France, Israel, Italy, Japan, Korea, Republic of, Spain, Taiwan
-
Merck Sharp & Dohme LLCCompletedPneumococcal DiseaseUnited States, Belgium, Chile, France, South Africa, Thailand
-
Merck Sharp & Dohme LLCCompletedPneumococcal InfectionUnited States, Australia, Belgium, Chile, Germany, Korea, Republic of, New Zealand, Puerto Rico, Sweden, Taiwan, Turkey
-
Merck Sharp & Dohme LLCCompletedPneumonia, PneumococcalUnited States
-
Merck Sharp & Dohme LLCCompletedPneumococcal InfectionUnited States, Australia, Canada, Chile, Japan, Korea, Republic of, New Zealand, Poland